Send to

Choose Destination
Biologicals. 2003 Mar;31(1):9-16.

Inactivated rabies vaccine control and release: use of an ELISA method.

Author information

Agence Française de Sécurité Sanitaire des Produits de Santé, Direction des Laboratoires et des Contrôles, 321 avenue Jean Jaurès, 69007 Lyon, France.


Quality control of human rabies vaccines performed by National Control Laboratories (NCLs) prior to marketing vaccines batches requires in vivo and in vitro potency assays as requested by the relevant European Pharmacopoeia monographs, OMCLs guidelines and WHO technical recommendations. The aim of the present study was to check the suitability of an enzyme-linked immunosorbent assay (ELISA) using a virus neutralizing monoclonal antibody, directed to the rabies virus glycoprotein, to monitor the consistency of the lot to lot rabies vaccines production. Furthermore, this work was implemented to establish in house specifications for the glycoprotein content.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center